Hassanipour S, Delam H, Arab-Zozani M, Abdzadeh E, Hosseini SA, Nikbakht HA, Malakoutikhah M, Ashoobi MT, Fathalipour M, Salehiniya H, Riahi S. Survival rate of prostate Cancer in Asian countries: a systematic review and Meta-analysis. Ann Glob Health. 2020;86:2.

Article  PubMed  PubMed Central  Google Scholar 

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014;:CD009266.

Litwin MS, Tan HJ. The diagnosis and treatment of prostate Cancer: a review. JAMA. 2017;317:2532–42.

Article  PubMed  Google Scholar 

Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, diagnosis, Treatment options, and alternative approaches. Molecules. 2022;27:5730.

Article  PubMed  PubMed Central  Google Scholar 

Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398:1075–90.

Article  PubMed  Google Scholar 

Bernardes de Jesus B, Blasco MA. Telomerase at the intersection of cancer and aging. Trends Genet. 2013;29:513–20.

Article  PubMed  Google Scholar 

Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10:677–85.

Article  PubMed  Google Scholar 

Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The Tumor Microenvironment in the response to Immune Checkpoint Blockade therapies. Front Immunol. 2020;11:784.

Article  PubMed  PubMed Central  Google Scholar 

Liu D, Xu S, Chang T, Ma S, Wang K, Sun G, Chen S, Xu Y, Zhang H. Predicting prognosis and distinguishing cold and hot tumors in bladder Urothelial Carcinoma based on Necroptosis-Associated lncRNAs. Front Immunol. 2022;13:916800.

Article  PubMed  PubMed Central  Google Scholar 

Escudero-Lourdes C, Alvarado-Morales I, Tokar EJ. Stem cells as target for prostate cancer therapy: opportunities and challenges. Stem Cell Rev Rep. 2022;18:2833–51.

Article  PubMed  PubMed Central  Google Scholar 

Chow H, Ghosh PM, deVere White R, Evans CP, Dall’Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016;122:1897–904.

Article  PubMed  Google Scholar 

Sidaway P. Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC. Nat Rev Urol. 2016;13:124.

Article  PubMed  Google Scholar 

Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, et al. Predicting Time from Metastasis to overall survival in castration-resistant prostate Cancer: results from SEARCH. Clin Genitourin Cancer. 2017;15:60–e662.

Article  PubMed  Google Scholar 

Nair SS, Weil R, Dovey Z, Davis A, Tewari AK. The Tumor Microenvironment and Immunotherapy in prostate and bladder Cancer. Urol Clin North Am. 2020;47:e17–54.

Article  PubMed  Google Scholar 

Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705.

Article  PubMed  Google Scholar 

De Vitis M, Berardinelli F, Sgura A. Telomere length maintenance in Cancer: at the crossroad between Telomerase and Alternative Lengthening of telomeres (ALT). Int J Mol Sci. 2018;19:606.

Article  PubMed  PubMed Central  Google Scholar 

Zvereva MI, Shcherbakova DM, Dontsova OA. Telomerase: structure, functions, and activity regulation. Biochem (Mosc). 2010;75:1563–83.

Article  Google Scholar 

Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365–86.

Article  PubMed  PubMed Central  Google Scholar 

Wan X, Guan S, Hou Y, Qin Y, Zeng H, Yang L, Qiao Y, Liu S, Li Q, Jin T, Qiu Y, Liu M. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts. Theranostics. 2021;11:4975–91.

Article  PubMed  PubMed Central  Google Scholar 

Memon A, Lee WK. KLF10 as a tumor suppressor Gene and its TGF-β signaling. Cancers (Basel). 2018;10:161.

Article  PubMed  Google Scholar 

Song H, Huang XF, Hu SY, Lu LL, Yang XY. The LINC00261/MiR105-5p/SELL axis is involved in dysfunction of B cell and is associated with overall survival in hepatocellular carcinoma. PeerJ. 2022;10:e12588.

Article  PubMed  PubMed Central  Google Scholar 

Ma Y, Xu Y, Li L. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. Exp Ther Med. 2018;16:3195–201.

PubMed  PubMed Central  Google Scholar 

Xin Z, Li D, Mao F, Du Y, Wang X, Xu P, Li Z, Qian J, Yao J. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. J Cell Physiol. 2020;235:8416–23.

Article  PubMed  Google Scholar 

Chen P, He Z, Wang J, Xu J, Jiang X, Chen Y, Liu X, Jiang J. Hypoxia-Induced ZWINT mediates pancreatic Cancer proliferation by interacting with p53/p21. Front Cell Dev Biol. 2021;9:682131.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Qin Y, Wu G, Wang J, Cao J, Wang Y, Wu D, Yang K, Zhao Z, He L, Lyu J, Li H, Gu H. PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1. Oncogene. 2020;39:7196–208.

Article  PubMed  Google Scholar 

Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2005;102:3389–94.

Article  PubMed  PubMed Central  Google Scholar 

Yan J, Nie K, Mathew S, Tam Y, Cheng S, Knowles DM, Orazi A, Tam W. Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma. Blood Cancer J. 2014;4:e215.

Article  PubMed  PubMed Central  Google Scholar 

Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21:674–9.

Article  PubMed  Google Scholar 

Mizukoshi E, Kaneko S. Telomerase-targeted Cancer Immunotherapy. Int J Mol Sci. 2019;20:1823.

Article  PubMed  PubMed Central  Google Scholar 

Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–33.

Article  PubMed  Google Scholar 

Meng J, Liu Y, Guan S, Fan S, Zhou J, Zhang M, Liang C. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. Cancer Med. 2019;8(11):5202–13.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Pan S, Zhu B, Yu Z, Wang W. Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urol. 2021;21:29.

Article  PubMed  PubMed Central  Google Scholar 

Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational Landscape and Sensitivity to Immune Checkpoint blockers. Clin Cancer Res. 2016;22:4309–21.

Article  PubMed  Google Scholar 

Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12:eaaz3577.

Article  PubMed